Seeking Alpha

Perrigo (PRGO +0.5%) announces final FDA approval for its Ketoconazole Foam 2% treatment for...

Perrigo (PRGO +0.5%) announces final FDA approval for its Ketoconazole Foam 2% treatment for dermatitis in younger patients. The company has commenced shipping of the product and has 180 days of marketing exclusivity.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector